The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech, which may offer quicker production and greater efficacy than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback